MedTrace Logo

Prostate Cancer 18F-PSMA-1007 PET/CT Access Trial

NCT06489496 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-07-08

No results posted yet for this study

Summary

Primary objective:

• To determine if 18F-PSMA-1007 PET/CT imaging is effective at diagnosing prostate cancers and/or metastases compared to conventional imaging \[including CT, MRI, 99mTc-MDP Bone Scans as available\].

Secondary Objective:

* To determine safety by evaluating for adverse events
* To determine which conventional imaging is being performed when 18F-PSMA-1007 PET/CT imaging is available

Conditions

Interventions

DIAGNOSTIC_TEST

18F-1007 PSMA PSMA PET/CT

Each patient will receive an IV injection 18F-PSMA-1007 PET/CT. PET/CT Imaging will be conducted beginning 90-120 minutes after an injection of 4 MBq/kg (max 400 MBq +/- 15%) 18F-PSMA-1007 in patients.

Sponsors & Collaborators

  • Alberta Health services

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2029-10-01
Completion
2030-10-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06489496 on ClinicalTrials.gov